

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

TICKLE, et al.

Serial No. 10/690,991

Filed: October 23, 2003

For: CRYSTAL STRUCTURE OF CYTOCHROME P450



Atty. Ref.: 620-282

Group: 1656

Examiner: NASHED, Nashaat T

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 19, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☒ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

12/20/2005 JADD01 00000117 10690991

03 FC:1006

180.00 OP

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:


- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☒ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

TICKLE, et al.
Serial No. 10/690,991

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

~~ATTY. DOCKET NO.~~

620-282

APPLICANT

TICKLE, et al.

FILING DATE

October 23, 2003

SERIAL NO.

10/690,991

(Use several sheets if necessary)

GROUP

1656

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Boddupalli et al, Proc. Natl. Acad. Sci., 1992, Vol. 89, pp 5567-5571
	Shimizu et al, Journal of Inorganic Biochemistry 81 (2000) 191-205
	Obayashi et al, Journal of Inorganic Biochemistry 82 (2000) 103-111
	Ost et al, Biochemistry 2001, 40, 13430-13438
	Ost et al, J. Am. Chem. Soc. 2003, 125, 15010-15020
	Li et al, Acta Cryst. (1995), D51, 21-32
	Ravichandran et al, Science, 1993, Vol. 261, pp 731-736
	Poulos, The Journal of Biological Chemistry, 1982, Vol. 257, No. 17, 10427-10429
	Raag et al, Biochemistry 1991, 30, 11420-11429
	Hishiki et al, J. Biochem. 2000, 128, 965-974
	Vidakovic et al, Biochemistry, 1998, Vol. 37, No. 26, pp 9211-9219

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)